Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression

ObjectiveTo explore the efficacy of c in the multiline treatment of late-stage lung adenocarcinoma with Her-2 overexpression and epidermal growth factor receptor (EGFR) mutations.MethodsWe summarize the diagnosis and treatment of a female patient with EGFR 21L858R mutation combined with Her-2 overex...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Meiling Lan, Tianyun Wang, Diexiao Luo, Yan Chen, Wei Liang, Rui Kong, Qichao Xie
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2024-12-01
Σειρά:	Frontiers in Oncology
Θέματα:	HER-2 overexpression epidermal growth factor receptor lung adenocarcinoma disitamab vedotin efficacy multiline treatment
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1472545/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!